

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
(Incorporated in the Cayman Islands with limited liability)  
(Stock code: 1548)

**VOLUNTARY ANNOUNCEMENT**  
**LEGEND BIOTECH ANNOUNCES PRELIMINARY SALES FOR**  
**CARVYKTI® FOR THE QUARTER ENDED 31 DECEMBER 2024**

This is a voluntary announcement made by GenScript Biotech Corporation (the “**Company**”).

References are made to the announcements of the Company dated April 16, 2024, July 17, 2024 and October 15, 2024 in relation to the preliminary sales of CARVYKTI® for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024 respectively.

The board of directors (“the **Board**”) of the Company is pleased to announce that Legend Biotech Corporation (“**Legend Biotech**”), an associate of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States (“**U.S.**”), has filed a Form 6-K with the United States Securities and Exchange Commission (the “**U.S. SEC**”) on January 22, 2025 (New York time) (after trading hours on January 22, 2025 in Hong Kong) and announced that CARVYKTI® generated approximately US\$334 million in net trade sales during the quarter ended December 31, 2024. This is pursuant to the Collaboration and License Agreement dated December 21, 2017 between Legend Biotech and Janssen Biotech, Inc. (“**Janssen**”). The net trade sales figure is based on information provided to Legend Biotech by Janssen, and neither Legend Biotech nor the Company have independently verified the accuracy of such sales figure. For details, please refer to the full Form 6-K as published on the U.S. SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000117184325000360/0001171843-25-000360-index.html>.

The sales figure is based on information available to Legend Biotech as of the date of this announcement, and the determination of the amount of any revenue or gross profit to be recorded in Legend Biotech’s consolidated statement of operations is subject to completion by management of Legend Biotech of its financial statements as of and for the period ended December 31, 2024. Legend Biotech’s independent registered public accountants have not audited, reviewed or performed any procedures with respect to this data and accordingly they have not expressed an opinion or provided any other form of assurance with respect thereto.

**Cautionary Note Regarding Forward-Looking Statements**

Statements in this announcement about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to CARVYKTI®, including Legend Biotech’s expectations for net trade sales and

resulting gross profit of CARVYKTI®. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend Biotech’s third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general public pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of the Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 19, 2024. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this announcement as anticipated, believed, estimated or expected. Any forward-looking statements contained in this announcement speak only as of the date of this announcement. The Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By order of the Board  
**Genscript Biotech Corporation**  
**Jiange Meng**  
*Chairman and Executive Director*

Hong Kong, January 22, 2025

*As at the date of this announcement, the executive Directors are Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Mr. Jiange Meng (“**Mr. Robin Meng**”), Ms. Ye Wang (“**Ms. Sally Wang**”) and Dr. Li Zhu; the non-executive Directors are Dr. Luquan Wang (“**Dr. Larry Wang**”) and Dr. Ross Grossman; and the independent non-executive Directors are Mr. Zumian Dai (“**Mr. Edward Dai**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Mr. Yiu Leung Andy Cheung, Dr. Chenyang Shi (“**Dr. Victor Shi**”), Dr. Alphonse Galdes and Dr. John Quelch.*